Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
about
Sequence of treatment in locally advanced and metastatic renal cell carcinomaCurrent status of targeted therapy for advanced renal cell carcinomaAngiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancerSequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance.Future perspectives for mTOR inhibitors in renal cell cancer treatment.CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma.Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.Second-line treatment for renal cell cancer.LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma.Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
P2860
Q26773653-007DFE52-AD53-4BC4-93AF-597843B55C4DQ35903850-28410773-37E4-4226-BAF1-DDBA4EF05FC3Q37081930-D2AA51A5-DAB3-42A8-ABB1-6575157EDEB0Q38016794-2864CE62-9259-4011-AD94-4544113DD268Q38072402-73E352C6-204F-4AA9-8545-F3944C65D4D9Q38372445-38B0DAF2-7A54-4262-9D6C-5CFAF0399106Q38978463-28802D3F-8436-43D8-88A2-88876B3EB5CCQ39008859-FDB3BF2E-D52B-4184-A805-93EFFA1E79C6Q40074627-F57DC39C-E141-4CFE-97ED-30B46AA18053Q41232235-2B09BA42-E7DE-4575-A61A-A00B2B42CF8BQ42551794-260972B5-7B83-4290-B7C3-7E537209D164Q42627880-4C7A5899-76C6-412E-A2F0-838ECB81272FQ43613506-D8149FBE-5469-4C6A-A522-9FB39EB0DD69Q47650946-E24C85B4-B8F0-445C-89E8-656A4ADCD65FQ55064954-BBAC9CEF-CC78-442F-8EA5-0028D7A6C41B
P2860
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Treatment of everolimus-resist ...... with VEGF-targeted therapies.
@ast
Treatment of everolimus-resist ...... with VEGF-targeted therapies.
@en
type
label
Treatment of everolimus-resist ...... with VEGF-targeted therapies.
@ast
Treatment of everolimus-resist ...... with VEGF-targeted therapies.
@en
prefLabel
Treatment of everolimus-resist ...... with VEGF-targeted therapies.
@ast
Treatment of everolimus-resist ...... with VEGF-targeted therapies.
@en
P2093
P2860
P356
P1476
Treatment of everolimus-resist ...... with VEGF-targeted therapies.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2011.389
P407
P577
2011-10-27T00:00:00Z